Edition:
United Kingdom

Uniqure NV (QURE.OQ)

QURE.OQ on NASDAQ Stock Exchange Global Select Market

17.37USD
15 Dec 2017
Change (% chg)

$-0.23 (-1.31%)
Prev Close
$17.60
Open
$17.51
Day's High
$17.58
Day's Low
$17.07
Volume
546,762
Avg. Vol
144,873
52-wk High
$21.35
52-wk Low
$4.74

Latest Key Developments (Source: Significant Developments)

UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Uniqure Nv ::UNIQURE ANNOUNCES UPDATED, LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 IN PATIENTS WITH SEVERE HEMOPHILIA B.UNIQURE -AAV5-BASED AMT-060 REMAINS SAFE,WELL-TOLERATED WITH UPTO 2 YEARS OF FOLLOW-UP,WITH NO NEW SERIOUS ADVERSE EVENTS,NO DEVELOPMENT OF INHIBITORS.  Full Article

Uniqure Q3 loss per share $0.40
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Uniqure Nv ::Uniqure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

UniQure reports Q3 loss $0.40/shr
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - UniQure Nv :UniQure announces third quarter 2017 financial results and recent company progress.Q3 loss per share $0.40.Q3 revenue $2.3 million versus $7.2 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Uniqure NV says ‍priced its underwritten public offering of 5 mln shares at $18.25 per share​
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Uniqure NV -:Uniqure announces pricing of its public offering.Uniqure NV says ‍announced pricing of its underwritten public offering of 5 million of its ordinary shares at a public offering price of $18.25 per share​.  Full Article

Uniqure announces proposed public offering
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Uniqure NV ::Uniqure announces proposed public offering.Uniqure NV - ‍ commenced an underwritten public offering of 5 million of its ordinary shares.  Full Article

uniQure acquires patent family providing broad protection of hyperactive padua variant of factor IX
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - uniQure Nv :uniQure strengthens intellectual property portfolio with acquisition of patent family providing broad protection of the hyperactive padua variant of factor ix (FIX-padua).  Full Article

Uniqure announces AMT-061 to enter pivotal study in 2018
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Uniqure Nv :Uniqure announces Hemophilia B gene therapy program to enter pivotal study with FIX-Padua variant in 2018.Uniqure NV - ‍plans to initiate pivotal study with enhanced AMT-061 in 2018​.Uniqure nv - ‍acquired patent family that covers FIX-Padua variant and its use in gene therapy for treatment of Coagulopathies, including Hemophilia B​.Uniqure - ‍FDA agreed AMT-061 will be included under existing breakthrough therapy designation and IND for AMT-060​.Uniqure NV - ‍EMA also has agreed that AMT-061 will be included under current prime designation​.  Full Article

Uniqure appoints Matthew Kapusta as chief executive officer
Monday, 19 Dec 2016 

Uniqure NV : Uniqure appoints Matthew Kapusta as chief executive officer . Uniqure NV says Kapusta will continue to serve as an executive member of uniqure board of directors .Uniqure NV says Matthew Kapusta has served as interim CEO since September 2016.  Full Article

Uniqure posts Q2 loss per share of EUR 0.77
Thursday, 25 Aug 2016 

Uniqure NV : Uniqure announces financial results for second quarter 2016 and update on company progress . Q2 loss per share EUR 0.77 . Q2 earnings per share view EUR -0.78 -- Thomson Reuters I/B/E/S . Uniqure says data from Sanfilippo B And Parkinson's disease studies expected in Q1 2017 .Uniqure says additional data on AMT-060 in Hemophilia B expected later this year.  Full Article

Uniqure Q2 loss per share eur 0.77
Thursday, 25 Aug 2016 

Uniqure Nv : Uniqure announces financial results for second quarter 2016 and update on company progress . Q2 loss per share eur 0.77 .Q2 earnings per share view eur -0.78 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-UniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial Of AMT-060 In Patients With Severe Hemophilia B

* UNIQURE ANNOUNCES UPDATED, LONG-TERM CLINICAL DATA FROM ONGOING PHASE I/II TRIAL OF AMT-060 IN PATIENTS WITH SEVERE HEMOPHILIA B